Status:
TERMINATED
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
35-75 years
Phase:
PHASE3
Brief Summary
This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inha...
Detailed Description
Pfizer announced in October 2007 that it would stop marketing Exubera. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marke...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
Exclusion
- COPD
- Asthma
- Smoking Pregnancy
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
635 Patients enrolled
Trial Details
Trial ID
NCT00136916
Start Date
June 1 2002
End Date
December 1 2008
Last Update
February 18 2010
Active Locations (92)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States, 85016
2
Pfizer Investigational Site
Tucson, Arizona, United States, 85715
3
Pfizer Investigational Site
Fresno, California, United States, 93720
4
Pfizer Investigational Site
Greenbrae, California, United States, 94904